A multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03).
Feng Wen(Sichuan University), Yali Shen(Sichuan University), Tianhai Lin(Sichuan University), Peng Zhang(Sichuan University), Min Ren(Sichuan University), Jing Deng(Sichuan University), Mengni Zhang(Sichuan University), Xiaonan Zheng(Sichuan University), Ping Tan(Sichuan University)
Cited by 3
Related Papers
Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus
|Nature Genetics|2011|284
A Nanostrategy for Efficient Imaging‐Guided Antitumor Therapy through a Stimuli‐Responsive Branched Polymeric Prodrug
|Advanced Science|2020|205
Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma
|Nature Communications|2021|167
Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma
|Signal Transduction and Targeted Therapy|2023|76
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours
|Neuroendocrinology|2018|55